Why the study?
Does losartan alter renal hemodynamics, microalbuminuria, and uric acid metabolism in patients with essential hypertension?
Population
10 patients with essential hypertension
Comparison
Losartan 50 mg/day for 1 month vs 15-day single-blind placebo run-in period
Design
Cohort, single-blind
Follow-up
1 month
Key result
In patients with essential hypertension, 1-month treatment with losartan 50 mg/day preserved GFR (96 vs 100 ml/min/1.73 m2) and significantly decreased microalbuminuria (40 vs 57 mg/24 h, P<0.05).
Authors
Loading...
Losartan preserved GFR/RPF while reducing microalbuminuria and uric acid; hypothesis-generating for larger trials before practice change.
Does losartan alter renal hemodynamics, microalbuminuria, and uric acid metabolism in patients with essential hypertension?
Absolute Event Rate: 96% vs 100%
Losartan preserves renal hemodynamics while significantly reducing microalbuminuria and serum uric acid in patients with essential hypertension.
Fauvel et al. (1996) studied Essential hypertension (n=10). Losartan vs. Placebo run-in was evaluated on Glomerular filtration rate (GFR). In patients with essential hypertension, 1-month treatment with losartan 50 mg/day preserved GFR (96 vs 100 ml/min/1.73 m2) and significantly decreased microalbuminuria (40 vs 57 mg/24 h, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: